Education
About Us
Working with TipRanks
Follow Us
Nuvectis Pharma (NVCT)
NASDAQ:NVCT
Total Valuation
Nuvectis Pharma has a market cap or net worth of $256.37M. The enterprise value is $86.94M.
Market Cap$256.37M
Enterprise Value$86.94M
Share Statistics
Nuvectis Pharma has 23,391,499 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,391,499
Owned by Insiders43.13%
Owned by Institutions1.89%
Financial Efficiency
Nuvectis Pharma’s return on equity (ROE) is -1.96 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)-1.96
Return on Assets (ROA)-1.02
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee0.00
Profits Per Employee-1.46M
Employee Count13
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nuvectis Pharma is -4.87. Nuvectis Pharma’s PEG ratio is 0.22.
PE Ratio-4.87
PS Ratio―
PB Ratio9.53
Price to Fair Value9.53
Price to FCF-7.56
Price to Operating Cash Flow-7.56
PEG Ratio0.22
Income Statement
In the last 12 months, Nuvectis Pharma had revenue of 0.00 and earned -19.00M in profits. Earnings per share was -1.11.
Revenue0.00
Gross Profit0.00
Operating Income0.00
Pretax Income-19.00M
Net Income-19.00M
EBITDA0.00
Earnings Per Share (EPS)-1.11
Cash Flow
In the last 12 months, operating cash flow was -12.25M and capital expenditures 0.00, giving a free cash flow of -12.25M billion.
Operating Cash Flow-12.25M
Free Cash Flow-12.25M
Free Cash Flow per Share-0.52
Dividends & Yields
Nuvectis Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.74
52-Week Price Change68.62%
50-Day Moving Average8.34
200-Day Moving Average6.88
Relative Strength Index (RSI)64.16
Average Volume (3m)128.63K
Important Dates
Nuvectis Pharma upcoming earnings date is May 13, 2025, TBA Not Confirmed.
Last Earnings DateFeb 25, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Nuvectis Pharma as a current ratio of 2.09, with Debt / Equity ratio of 0.00%
Current Ratio2.09
Quick Ratio2.09
Debt to Market Cap0.00
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Nuvectis Pharma has paid -19.00M in taxes.
Income Tax-19.00M
Effective Tax Rate1.00
Enterprise Valuation
Nuvectis Pharma EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -6.05.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow-6.05
EV to Operating Cash Flow-6.05
Balance Sheet
Nuvectis Pharma has $18.53M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$18.53M billion.
Cash & Marketable Securities$18.53M
Total Debt$0.00
Net Cash-$18.53M
Net Cash Per Share-$0.79
Tangible Book Value Per Share$0.57
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Nuvectis Pharma is $16.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$16.25
Price Target Upside48.27% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast22.99%